































In yeast, chronological senescence (CS) is defined as 
loss of viability of yeast cells grown in confluent state 
[1-10]. Viability is determined as the ability to resume 
replication in fresh medium. CS is genetically regulated 
and inactivation of numerous genes including TOR 
(Target of Rapamycin) extends lifespan [2, 11-23]. 
Furthermore, rapamycin, an inhibitor of TOR, 
decelerates CS in yeast [24]. Noteworthy, the TOR 
(target of rapamycin) pathway is involved in aging of 
variety of species from worm to mammals [25-28]. 
Some other genes identified in the yeast model turned 
out to be involved in organismal aging and age-related 
diseases in mammals [29-38]. CS is often compared to 
aging of postmitotic cells in the organism. However, as 
recently discussed, the link between CS and organismal 
aging is not immediately apparent but indirectly relies 
on common genetic pathways [39].  
 
Since yeasts are unicellular organisms, CS should be 

































culture.  There are two types of senescence of 
mammalian cells in culture: replicative and accelerated 
(also known as premature or stress-induced 
senescence). Yeast replicative senescence corresponds 
to replicative senescence in rodent cells. Then at first 
glance, yeast CS is analogous to accelerated cellular 
senescence.  The analogy is seemingly strengthened by 
the involvement of mTOR in senescent phenotype of 
mammalian cells [40-46]. In proliferating cells, mTOR 
is active, thus driving cell growth in size, which is 
balanced by cell division. When cell cycle is blocked by 
p21 or p16, for instance, but mTOR is still active, then 
mTOR drives cellular senescence [40, 46, 47]. By 
deactivating mTOR, rapamycin prevents conversion of 
quiescence into senescence or, in other words, prevents 
gerogenic conversion (geroconversion) during cell cycle 
arrest [41, 46]. 
 
Yet accelerated senescence is not analogous to yeast 
CS. Accelerated cellular senescence is not caused by 
medium acidification. Senescent cells are large, flat, 























cell  senescence,  also  decreased  lactate  production  and  decelerated  CS.  We  discuss  that  although  CS  does  not  mimic
organismal aging, the same signal transduction pathways that drive CS also drive aging. 
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density mTOR is spontaneously deactivated thus 
suppressing geroconversion (manuscript in preparation). 
So there is no known mammalian analogy to yeast CS. 
Given that yeast aging research has been so fruitful in 
identification of pathways involved in organismal 
aging, [1, 3, 48-51] it is important to recognize relevant 
mammalian cell model for CS.  
 
We realized that replica of CS is so trivial that it 
remains unnamed and ignored, although this 
phenomenon is known to any cancer researcher. If a 
flask with cancer cells is forgotten (neglected) in the 
incubator, cells become over-confluent, overgrow, and 
loose viability. And this is exactly what would be called 
chronological aging (in yeast). Here we investigated 
mechanisms of chronological senescence (CS) in 




TOR-dependent CS in HT-p21-9 cells 
 
For initial experiments we chose HT-p21-9 cells, because 
these cells were extensively studied as a model of 
conventional cellular senescence [52, 41]. Importantly, 
these cells rapidly turn media yellow. Acidification of the 
medium is evident by transition of the color of phenol red 
(a pH indicator) from pink-red to yellow over the pH 
range 7.4 to 6.8.  The color of phenol red is a convenient 
measure of pH. In dense cell culture, the medium 
becomes acidic (yellow) (Fig. 1A: top panel – control 
(C). Rapamycin renders the color pinkish. After 
recording the color by photography, media were collected 
for further analysis (lactate levels, cytotoxicity) and equal 
volumes of trypsinized cells were re-plated in larger 
plates in fresh medium (Fig. 1 A, bottom panel) and 
colonies were allowed to grow for 7 days. In control, 
cells lost the replicative capacity and did not form 
colonies in fresh medium (Fig. 1A, bottom panel). 
Rapamycin prevented loss of viability (Fig. 1A). Loss of 
viability, over time (Fig. 1B), is chronological senescence 
(CS). At initial cell densities of 40,000 and 80,000 cells 
per well (Fig. 1 B), the major drop in viability occurred at 
day 5 and day 4, respectively (Fig. 1B). The most 
dramatic effect of rapamycin was observed, when control 
cultures almost completely lost their viability. To 
quantify the viability, we counted cells after 7 days of re-
growth in fresh culture (Fig. 1C). There was a dramatic 
decrease in viability after 4 and 5 days in control wells, 
which was prevented by rapamycin (Fig. 1 C).  
 
Time course of lactate production 
 
At both cell densities,  lactic  acid  (LA)  concentrations  
reached the maximal level of ~30 mM on day 3 and day 
4, respectively (Fig. 1D). Noteworthy, these maximal 
levels of LA were achieved a day before the major loss 
of viability (Fig. 1 D versus C).  Rapamycin decreased 
levels of LA, so that LA concentration approximated to 
the maximal level by day 6-7. A comparison of LA 
levels and CS time points suggests that levels of LA 
above 30 mM may make medium toxic: then cells loose 
viability and this prevents further accumulation of LA. 
 
Protection by rapamycin is indirect 
 
Next, we tested the effect of conditioned medium (CM) 
that was collected from the dense culture and applied to 
cells plated at low density.  Such CM was deadly, 
causing loss of viability in low cell density. This 
allowed us to investigate the mechanism of action of 
rapamycin: direct versus indirect. One possibility is that 
rapamycin protects cells directly by increasing 
resistance to cell death caused by deadly CM. Another 
possibility is that CM produced in the presence of 
rapamycin would be less deadly. We tested CM 
produced in the presence of rapamycin (R-CM) versus 
CM with rapamycin being added after CM collection 
(CM+R). Both types of CM were added to low density 
HT-p21-9 and HCT116 cells for 3 days and then the 
cells were grown in fresh medium. CM+R was as toxic 
as CM, whereas R-CM was significantly less toxic (Fig. 
2). We conclude that rapamycin does not protect cells 
directly, but instead changes the property of CM. As we 
have already shown, rapamycin decreased levels of LA 
(Fig. 1D). 
 
Lactate poisoning  
 
Next we tested whether LA is toxic.  Addition of 40 
mM lactate to fresh medium rendered it “absolutely 
deadly” (Fig. 2 A). Viability IC50 was around 20-30 
mM LA, depending on cell line. Noteworthy, color of 
the medium containing 30 mM lactate was similar to 
yellow color of CM in the stationary culture, when cells 
undergo CS. This was confirmed by measurements of 
LA in such deadly CM (34.6 ± 1 mM). So LA levels 
slightly above 30 mM were maximally achievable, 
killing cells and thus preventing further accumulation of 
LA. 
 
There are 2 possibilities that are not mutually exclusive: 
1) LA is toxic by itself and is the only cause of CS. 
Rapamycin, which decreases levels of LA, 
simultaneously decreases toxicity of CM; 2) production 
of 30 mM lactate requires metabolism of 15 mM 
glucose.  In principle, exhaustion of glucose may 
contribute to CM toxicity.  However, addition of   
glucose to CM did not decrease its toxicity (Fig. 2 B).  
   







































Thus, LA was the main cause of toxicity. Next, we 
tested whether this toxicity was due to LA acidity. To 
neutralize pH, we added NaOH to cells plated in high 
density after one day of cultivation. At concentrations 
(0.5-1 mM) NaOH shifted the medium color from 
yellow to pink and decreased CS (Fig. S1). We 
conclude that it is acidity of LA that is deleterious for 
the cells. 
 
Gerosuppressants decrease lactate levels and CS 
 
Recently we have demonstrated that agents that 
deactivate the mTOR pathway decelerate premature 
(p21-induced) senescence in HT-p21-9 cells [41, 53, 









































from quiescence to senescence (geroconversion), we 
named them gero-suppressants [55]. Here we evaluated 
the effect of gero-suppressants on CS, using rapamycin 
as a positive control (Fig. 3). Inhibitors of PI-3K and 
MEK, LY294002 and U0126, respectively, decreased 
acidosis (Fig. 3 A), lactic acid production (Fig. 3 B) and 
dramatically decreased CS in HT-p21-9 and HCT116 
cells (Fig. 3 C-D). Suppression of CS correlated with 
inhibition of LA production in both cell lines. The 
antioxidant N-acetyl-L-cysteine (NAC) decreased LA 
production preferentially in HT-p21-9 cells and also 
prevented CS in the same cell line. CGK733, in 
contrast, was preferentially effective in HCT116 cells 
(Fig. 3). Finally, metformin did not affect either LA 


















































































Noteworthy, free radicals and oxidative stress can 
activate Akt/mTOR and vice versa active TOR may 
promote ROS [9, 56]. Therefore, inhibition of ROS by 
NAC is expected to decrease not only ROS levels but 
also mTOR activity. In fact, NAC inhibited CS in a dose-
dependent manner with maximal effect at 20 mM (higher 
concentrations were toxic) (Fig. 4 A). In high cell 
density, mTOR was spontaneously deactivated after first 
day in culture. NAC inhibited the Akt/mTOR pathway by 
6 hrs (Fig. 4B, 6 hrs), before mTOR becomes 
spontaneously deactivated. Noteworthy, the ATM 












































NAC.  (A)  After  4  days,  the  plates  were  photographed  (upper
panel)  and  lactate  concentrations  were  measured  in  media
(lower panel). (B) An equal volume of attached cells (an aliquot
of 2%) was plated in 6 well plates. After 7 days, colonies were
stained  with  Crystal  Violet  (upper  panel)  or  total  numbers  of
cells per well were determined by counting (low panel). 
Figure 4. Effects of NAC and CGK733 on CS and mTOR.




legend  for  Figure  1.  (B)  HT‐p21‐9  cells  were  plated  at  high 
density with indicated agents or left untreated (C) and allowed 
to attach for 6 hrs. Then, one set was lysed (Day 0, 6 hr) and 
second  set  was  lysed  after  24  hrs  treatment  (Day  1). 
Immunoblot was performed using indicated antibodies. 
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culture (Fig. 4 and Fig. S3). Still, rapamycin and other 
mTOR inhibitors suppressed CS very effectively. This 
suggests that the activity of mTOR during the first day 
(before spontaneous deactivation of mTOR) determines 
cell fate.  
 
Effects of pre-conditions 
 
We have noticed that time course of CS was slightly 
variable in different experiments (compare HCT116 
cells in Fig. 3 and Fig. 6), even if cells were plated at 
the same densities and conditions. We reasoned that this 
may be due to different pre-conditions, given that 
mTOR becomes spontaneously deactivated in culture 
over time. This suggests that cells from the fresh culture 
will lose viability faster compared with those from the 
old culture. We tested this prediction. 80,000 cells from 
either old or fresh culture were plated in 96-wells in 




































measuring their viability. In fact, cells derived from 
“old pre-culture” retained viability longer (Fig. S2). 
Whereas rapamycin prevented CS in cells derived from 
fresh pre-culture, its effect was minimal in old pre-
culture cells (Fig. S2). This result is in agreement with 
the data that mTOR is already inhibited in old pre-
culture. 
 
Lactate production vs apoptosis-reluctance as 
determinant of CS 
 
We next compared 3 cell lines: HT-p21-9, HCT116 and 
HCT116-Bax-/-, a clone of HCT116 cells lacking Bax 
(Fig. 5 and 6). HCT-Bax-/- cells are apoptosis-reluctant 
[57, 58]. Cells were plated in 2 cell densities (80,000 
and 20,000 cells per well).  At high cell density on day 
4, HT-p21-9 cells lost viability, which was prevented by 
rapamycin (Fig. 5B). In contrast, HCT116 and HCT-
Bax-/- cells retained viability at that time point (in this 



















































































In comparison with HCT116 cells, HT-p21-9 cells 
produced considerably more LA during the first day, 
which reached sub-lethal levels at that time (Fig. 5A). 
This demonstrated that levels of LA reached on the first 
day determine CS. However, HCT-Bax-/- cells, which 
were less prone to CS produced more lactate than 
HCT116 parental cells, indicating that resistance to 
apoptosis can also determine the viability. That was 
confirmed by direct testing of lactate on cell viability: 
HCT-Bax-/- cells appeared to be slightly more resistant 
to 30 mM LA than parental cells (Fig. 7). Still, the 
difference in resistance was relatively small. The major 
factor that determined CS was the rate of LA production 
during the first day in culture (Fig. 5, 6). At low cell 
density, the difference in LA production was the most 








































glycolytic, whereas HCT116 cells were the least 
glycolytic (Fig. 6A, day 1). By day 4, HT-p21-9 cells 
produced near-lethal levels of lactate (Fig. 6A). 
Accordingly, HT-p21-9 cells lost viability by day 8 
(Fig. 6 B, C).  
 
A forced increase in lactate levels accelerated CS 
 
If mTOR-dependent lactate production (rather than the 
activity of mTOR per se) is responsible for CS, then 
anoxia will accelerate CS. Anoxia and hypoxia induce 
(hypoxia-inducible factor) HIF-1 and this effect is not 
blocked by rapamycin  (Fig.  S3). Furthermore, 
hypoxia/anoxia decreases the activity of the mTOR 
pathway [59, 60]. So in anoxia LA production is forced 










www.impactaging.com                      6                                  AGING, November 2011, Vol.3 No.11diminish mTOR-dependent glycolysis by deactivating 
mTOR. Not surprisingly, relationship between aging 







































In anoxia experiments, cells were cultivated without 
oxygen for 3 days: from day 1 to day 4 (Fig. 5, 6). At 
high cell density on day 4, HT-p21-9 cells lost viability, 
which partially was prevented by rapamycin (Fig. 5 B, 
C). Furthermore, even HCT116 and HCT-Bax-/- cells 
lost viability in anoxia but not in normoxia (Fig. 5, 6).  
Yet, final levels of LA were almost identical in both 
normoxia and anoxia because CS prevented further 
accumulation of lactate (Fig. 5A, Fig 6A).  
 
Rapamycin decelerated CS under both normoxia and 
anoxia. This might be due to a decrease in lactate 
production on the first day (especially in high density 
cultures, Fig. 5A) before cells were placed in anoxia. 
Alternatively, rapamycin may decrease cellular 
metabolism in anoxia, which would indicate that the 
effect of rapamycin was not due to its effects on 
respiration. Experiments here were not intended to 
determine whether the protective effect of rapamycin 
was independent of respiration. Further studies are 
under way to determine the effect of rapamycin on 
glycolysis under anoxia versus normoxia. 
 
Suppression of CS by rapamycin was not due to its 
cytostatic effect  
 
Rapamycin is moderately cytostatic in some cell lines 
including HT-p21-9 cells. However, the cytostatic effect 
in low cell density cannot account for deceleration of 
CS in high cell density. First, at high cell densities with 
a limited proliferation window, the cytostatic effect of 
rapamycin was undetectable. We plated HT-p21-9 cells 
in a wide range of initial cell densities (Fig. 8) from 
35000 to 560000 cells per well with and without IPTG. 
In HT-p21-9 cells, IPTG induces ectopic p21 and 
causes cell cycle arrest [52], thus ensuring a constant 
number of cells.  
 
The acidity (yellow color) of the medium was 
proportional to initial cell numbers up to 140000 (Fig. 8 
A) and corresponded to deadly levels of LA (Fig. 8 B). 
Rapamycin decreased levels of lactate. Noteworthy, 
highest levels of lactate were achieved at initial density 
140000 (Fig. 8 B), but not at higher densities. At initial 
density of 280000 and 560000, all cells died within 
several days (Fig. 9, upper panel). These cells were 
floating and did not produce any colonies (Fig. 9, lower 
panel). On day 4, numbers of adherent (alive) cells were 
approximately identical at initial plating densities 
between 35000 and 140000 (Fig. 9, upper panel). This 
means that cells underwent 2, 1, and 0 divisions when 
plated at initial densities of 35000, 70000 and 140000, 
respectively. Most importantly, rapamycin did not affect 
the number of live cells (Fig. 9, upper panel); even 
though it decreased LA levels (Fig. 8 B). Despite 
rapamycin did not have an effect on the number of live 
cells, it dramatically increased the number of cells with 
replicative potential  (Fig. 9, lower panel). 
 
At initial density of 140000 cells, cells did not 
proliferate and did not die (Fig. 9). At this density, the 
level of lactate was maximal as well as the effect of 
rapamycin on CS (Fig. 8). Furthermore, we excluded 
the cytostatic effect of rapamycin by mixing IPTG- 
arrested HT-p21-9 (GFP-positive) cells with a few 
HCT116 cells, termed here as indicator cells. Since HT-
p21-9 cells were already arrested by IPTG, rapamycin 
could not possibly arrest them further. The indicator 
HCT116 cells are not sensitive to cytostatic effects of 
Figure  7.  Lactate  resistance  of  HT‐p21‐9,  HCT116  and
HCT116‐Bax‐/‐ cells. HCT116 cells, HCT‐Bax‐/‐ and HT‐p21‐9
cells  were  plated  in  96‐well  plates  at  low  density  (2000
cells/well)  and  treated  with  a  range  of  lactic  acid  (LA)
concentrations  or  conditioned  medium  (CM).  After  3  days,
medium was changed to fresh medium and cells were allowed to
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proliferation of the indicator HCT116 cells, the small 
number of indicator cells could not significantly 
contribute to lactate production. We treated the cell 
mixture (80000 HT-p21-9 cells mixed with 2000 
indicator cells) with IPTG (Fig. 10). After 4 days of 
incubation, small aliquots of cells were re-plated in 
fresh medium with IPTG to preclude proliferation of 
HT-p21-9 cells.  As shown in Figure 10A, rapamycin 
dramatically increased a number of colonies. It was 
confirmed by microscopy that only HCT116 cells 
formed colonies, whereas IPTG-arrested HT-p21-9 
(green) cells became senescent  (large morphology of 




Here we described a mammalian model of yeast-like 
chronological senescence (CS). Regardless of how 



































For both yeast and cancer cells, CS can be defined as 
loss of replicative viability in a stationary culture.  
 
Cancer cells with high glycolysis resemble yeast cells 
[62-65].  The most predictive sign of CS is yellow color 
of the medium, which indicates pH. Lactate and 
conditioned medium (CM) by were deadly in cells 
plated in low density. Furthermore, levels of lactate that 
caused CS coincided with maximally reachable lactate 
levels in the culture. Neutralization of the acidity 
prevented CS. Similarly, in some studies in yeast, loss 
of replicative ability was attributed to acidosis [39, 66-
68]. The only difference is that mammalian cells produce 
lactic acid instead of acetic acid. Rapamycin decelerated 
CS. Rapamycin decreased lactate accumulation, keeping 
lactate levels below deadly levels. In other words, CS is a 
metabolic self-destruction or hypermetabolism-induced 
loss of replicative ability. By producing lactate, cells 
poison themselves and cannot resume replication in the 








































untreated  (C).  (A)  On  day  1,  plates  were  photographed.  (B)  On  Day  1  lactate  concentrations  were
measured in media. (C) On day 4 plates were photographed. (D) On Day 4 alive (attached) and dead
(floating)  cells  were  counted  in  wells  with  initial  plating  density  of  140,000 cells/well.  (E)  Replicative
viability of attached cells was measured as described in Materials and Methods and legend for Figure 1. 
   








































Still mechanisms of yeast CS are widely disputed and 
may depend on culture conditions [9, 18, 19, 22, 66-68]. 
Perhaps, mechanisms of mammalian CS may vary 
depending on initial cell densities, cell line, the 
propensity to apoptosis, levels of nutrients in the 
medium, initial mTOR activity, levels of oxygen and 
culture conditions prior to experiment. Also, we 
emphasize that our study was not intended to address 
the mechanisms of yeast CS. It neither resolves nor 
complicates the current debate in yeast aging research. 
The main goal of this study was to characterize “yeast-
like” senescence in human cells and its pharmacological 
manipulation and also to address the question whether 
CS mimics cellular aging in the organism. CS mimics 
tumor necrosis rather than aging of post-mitotic cells. 
So, literally, CS is not a physiological model of 
organismal aging. But the same signaling pathways 
(such as TOR) are involved in CS and aging (Fig. 11), 
making the model useful for drug and gene discovery.  
We have shown that agents that decrease lactate 
production decelerate CS. Specifically, agents that 
directly or indirectly inhibit mTOR such as rapamycin, 
LY294002, U106 and to a lesser extend NAC, all 
suppressed CS. What all these agents have in common 
is that they inhibit the mTOR pathway. Thus, the same 
agents that suppress CS also were shown to suppress the 
senescent phenotype or conversion from quiescence to 
senescence during cell cycle arrest in traditional models 








































Activation of growth factor receptors, Ras, Raf, PI3K, 
Akt, which all activate mTOR, are most common 
Figure 9. Effects of initial density and rapamycin on cell
proliferation,  survival  and  replicative  viability.
Experiment  was  performed  as  described  in  the  legend  for
Figure 8 (Upper panel).  Cell survival. Alive (attached) and dead





by indirect effects on abundant cells.  A  mixture  of  2000
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pathways also drive senescent phenotype, when the cell 
cycle is blocked [40, 53, 55]. The same pathways 
confirm highly glycolytic phenotype [84, 85], rendering 
cells prone to lactate-induced CS.  And the same 
oncogenic pathways are involved in aging from yeast to 
mammals [11, 86-88]. And tumor suppressors 
(including p53) that inhibit the mTOR pathway are 




















In line with previous proposals [11, 39], our work 
suggests that the same signaling pathways that are 
known to drive aging are also involved in glycolytic 
phenotype, which determines CS. Therefore, genetic 
and pharmacological manipulations that decelerate CS 
may also affect physiological aging. The same pathways 
(Ras, MEK and PI-3 K/Akt/mTOR) that render cells 
malignant and glycolytic are involved in aging. So the 
same agents that inhibit CS can also suppress malignant 
metabolism and organismal aging. In addition such 
agents may be beneficial during acute ischemia (as well 
as re-oxygenation) to prevent necrosis. Lactic acidosis 
is one of the complications of diabetes. Also, 
overproduction of lactate by tumors can lead to fatal 
lactic acidosis in cancer patients [94-96]. We suggest 
that rapamycin may be used to treat lactic acidosis both 
in diabetes and in cancer patients. Interestingly, stromal 
cells also overproduced lactate, thereby feeding the 
tumor [97-99]. We suggest that systemic rapamycin 
may decrease lactate production in the stroma.  
 
Pro-aging pathways are conserved in evolution. This 
may explain why screening for agents that decelerate 
yeast CS could be useful against age-related diseases, 
aging and cancer. In comparison with yeast, human 
cells are more relevant to human aging and drug 
discovery.  
In conclusion, CS is relevant to aging not because CS 
happens during physiological aging in the organism, but 
because the common genes and signaling pathways 
determine both CS and aging (Fig. 11). Here we 
discussed CS from the point of view of the aging 
research, as an analogy to yeast CS. From the cancer 
research point of view, we will discuss the implication 
of CS for tumor progression, aggressiveness and cancer 
therapy (Leontieva et al, Oncotarget, in press).  
 
MATERIALS AND METHODS 
 
Cell lines and reagents.  HT-p21-9 cells, derived from 
HT1080 human fibrosarcoma cells (ATCC, Manassas, 
VA), provided by Igor Roninson, were previously 
described [52, 41].  HT1080-p21-9 cells were cultured in 
high-glucose DMEM without pyruvate supplemented 
with FC2 serum (HyClone FetalClone II from Thermo 
Scientific, Logan, Utah). In HT-p21-9 cells, p21 
expression can be turned on or off using isopropyl-thio-
galactosidase (IPTG) [52, 41].  MCF-7 and HCT116 cell 
lines were obtained from ATCC (Manassas, VA). MCF-
7, breast cancer cell line was cultured in high-glucose 
DMEM (plus pyruvate) with 10% FBS. HCT-Bax/- cells 
were derived from HCT116, colorectal adenocarcinoma 
cell line, and were provided by Bert Vogelstein.   
Rapamycin was obtained from LC Laboratories (MA, 
USA) and dissolved in DMSO as 5 mM solution. IPTG 
(Invitrogen) was dissolved in water as 50 mg/ml stock 
solution and used in cell culture at final concentration of 
1.25-50 µg/ml. LY294002, CGK733, metformin, NAC, 
UO126 were obtained from Sigma-Aldrich. 
 
Immunoblot analysis.  Whole cell lysates were prepared 
using boiling lysis buffer (1%SDS, 10 mM Tris.HCl, 
pH 74.).  Equal amounts of proteins were separated on 
10% or gradient polyacrylamide gels and transferred to 
nitrocellulose membranes.  The following antibodies 
were used: rabbit anti-phospho-S6 (Ser235/236) and 
mouse anti-S6, rabbit anti-phospho AKT and anti-Akt 
from Cell Signaling Biotechnology; anti-actin antibody 
from Sigma-Aldrich and mouse anti-HIF-1a from BD 
Biosciences. Secondary anti-rabbit and anti-mouse HRP 
conjugated antibodies were from Cell Signaling 
Biotechnology.   
 
Preparation of conditioned medium: Conditioned 
medium (CM) from HT-p21-9 cells plated at high 
density (10
6 cells per 60 mm dish) and cultured for 4 
days. R-CM, cells were cultured in the presence of 500 
nM rapamycin. CM+R: 500 nM rapamycin was added 
to CM after collection of CM.  
 
Lactate assay was performed using L-Lactate assay kit 
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Replicative viability as measure of CS. Cells were 
plated at high initial density (see Fig. 1A) and cultured 
for 4-8 days. Then media with floating (dead cells) were 
removed, cells trypsinized and a small aliquot of 
attached cells was replated at low cell density in 6 well 
plates in fresh medium. After 6-8 days, colonies were 
stained with 1.0 % crystal violet and in replicate wells 
cells were trypzinised and counted. 
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Figure  S1.  Effect  of  NaOH  on  CS.  HT‐p21‐9  cells  were  plated  at
80,000/well in 96 well plates.  On day 1, 0.5 mM or 1 mM NaOH was added.
100 nM rapamycin (Rapa) was used as positive control. Cells were split on
day 5 (4 µl out of 200 µl culture per well into 6 well plates) as shown in Fig.
1A. Colonies were grown for 9 days and stained with Crystal Violet. 
 
Figure S2. HT1080 p21‐9 cells passaged the day before (fresh
culture) or cultured for 2 weeks without change of the medium
(old culture) plated at 80000 cells/well in 96‐well plates with or
without 500 nM rapamycin.  On day 4, cells were trypsinized and
equal volumes of adherent cells (2%) were re‐plated in 6 well
plates. After 7 days, colonies were stained with Crystal violet. 
Figure S3. HT‐p21‐9, HCT116 and HCT Bax‐/‐  cells were plated at high density (upper panel) and regular density (lower
panel) and on Day 1 was placed in either normoxia (Nor) or hypoxia (Hyp)  with or without 100 nM rapamycin (R) or left
untreated (C). Cells were lysed on day 1 (D1) and on day 3 (D3). Immunoblot was performed using indicated antibodies.
 